Opdivo Plus ASCT Ably Treats Classical Hodgkin’s Lymphoma Patients with Few Options, Study Says
News
Classical Hodgkin’s lymphoma patients who failed to respond to autologous stem cell transplant (patient-derived cells) showed “unprecedented” low relapse rates after being given Opdivo (nivolumab) followed by an allogeneic, or donor-derived, ... Read more